Stock Ratings | BNP Paribas initiated coverage of CRWV with an "outperform" rating and a price target of $192; while HC Wainwright lowered its price target for PRAX to $1,201, indicating a potential upside of 365.36%.
Genasys, Inc. GNSS | 0.00 | |
Abivax SA Sponsored ADR ABVX | 0.00 | |
Jade Biosciences, Inc. JBIO | 0.00 | |
Praxis Precision Medicines PRAX | 0.00 | |
Credo Technology CRDO | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Ascendiant Capital: Maintaining a "buy" rating on Genasys ( Genasys, Inc.(GNSS.US) ), while raising the price target from $5.5 to $6.
Citizens: Maintaining Abivax's ( Abivax SA Sponsored ADR(ABVX.US) ) rating at "Outperforming the Market," while raising the price target from $131 to $187.
Wedbush: Maintaining its "Outperform" rating on Jade Biosciences Jade Biosciences, Inc.(JBIO.US) ), while raising its price target from $34 to $45.
HC Wainwright & Co.: Maintaining a "buy" rating on Praxis Precision Medicine ( Praxis Precision Medicines(PRAX.US) ), while lowering the price target from $1245 to $1201.
JP Morgan: Maintaining Credo Technology Group's ( Credo Technology(CRDO.US) rating at "overweight", while raising the price target from $230 to $250.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Genasys, Inc.(GNSS.US) | to lift | $6.0 | $2.03 | 195.57% | Ascendiant Capital |
| Abivax SA Sponsored ADR(ABVX.US) | to lift | $187.0 | $72.5 | 157.93% | Citizens |
| Jade Biosciences, Inc.(JBIO.US) | to lift | $45.0 | $17.75 | 153.52% | Wedbush |
| Unicycive Therapeutics(UNCY.US) | to lift | $18.0 | $7.23 | 148.96% | Benchmark |
| Aktis Oncology, Inc.(AKTS.US) | to lift | $35.0 | $20.26 | 72.75% | HC Wainwright & Co. |
| X4 Pharmaceuticals, Inc.(XFOR.US) | Initial classification | $12.0 | $4.04 | 197.03% | Leerink Partners |
| Praxis Precision Medicines(PRAX.US) | cut | $1201.0 | $258.08 | 365.36% | HC Wainwright & Co. |
| Praxis Precision Medicines(PRAX.US) | cut | $810.0 | $258.08 | 213.86% | BTIG |
| Oculis Holding AG(OCS.US) | cut | $38.0 | $12.29 | 209.19% | Baird |
| Praxis Precision Medicines(PRAX.US) | cut | $650.0 | $258.08 | 151.86% | Oppenheimer |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Baird: Maintaining a "neutral" rating on CrowdStrike Holdings CrowdStrike(CRWD.US) , while raising its price target from $460 to $490.
JP Morgan: Maintaining an "overweight" rating on CrowdStrike Holdings CrowdStrike(CRWD.US) ), while raising its price target from $475 to $800.
UBS: Maintaining a "buy" rating on Oracle Oracle Corporation(ORCL.US) ) stock, while raising the price target from $250 to $285.
Keybanc: Maintaining Sterling Construction's ( Sterling Infrastructure, Inc.(STRL.US) ) rating at "Overweight," while raising the price target from $889 to $922
Citigroup: Maintaining a "buy" rating on WDC ( Western Digital Corporation(WDC.US) ), while raising the price target from $500 to $685.
Susquehanna: Maintaining a "neutral" rating on XPO ( XPO, Inc.(XPO.US) ) stock, while raising the price target from $210 to $212.
First Coverage
BNP Paribas: CoreWeave ( CoreWeave(CRWV.US) ) initial rating at "outperforms the market", with a price target of $192.
BNP Paribas: Initial rating for Nebius Group ( NEBIUS(NBIS.US) ) stock at "neutral", with a target price of $255.
Piper Sandler: Initial rating for Take-Two Interactive Software, Inc.(TTWO.US) stock at "overweight", with a price target of $280.
Piper Sandler: Initial rating for Unity Software ( Unity Software, Inc.(U.US) ) stock at "overweight", with a price target raised to $40.
reduction
B of A Securities: Maintaining a "buy" rating on FedEx ( FedEx Corporation(FDX.US) ) stock, while lowering the price target from $440 to $376.
HSBC: Maintaining Google's A- rating ( Alphabet Inc. Class A(GOOGL.US) ) at "Buy", while lowering the target price from $435 to $420.
Mizuho: Downgraded its rating on Okta Okta(OKTA.US) ) stock to "neutral," while raising its price target from $110 to $125.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.